Optibiotix Health plc
OptiBiotix Health Plc is an AIM-listed (ticker OPTI; OTCQB: OPTBF) life sciences company that develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds to deliver health benefits, principally around weight management, gut health and sugar reduction. Its first-generation products are SlimBiome® (weight control) and WellBiome® (gut health), sold through international distributor and e-commerce networks, while its second-generation assets include SweetBiotix® (a high-fibre sugar substitute) and Microbiome Modulators, which are being commercialised via partnerships. The Group also retains equity stakes in two companies it spun out, SkinBioTherapeutics plc (SBTX) and ProBiotix Health plc (PBX, an associate).
FY2025 in sixty seconds
year to 31 Dec 2025 · approved 27 May 2026 · 60 pages · Companies House
OptiBiotix Health makes natural ingredients and supplements aimed at weight control, gut health and cutting sugar. In the year to 31 December 2025 its sales rose to £1.2m (+34.0%) from £870k the year before, but its loss after tax widened to £3.9m from £1.8m.
The company kept more of each pound of sales because it sold a better mix of products and controlled costs. The bigger loss came mainly from a large non-cash charge for shares and options awarded to staff. A fall in the value of its stake in SkinBioTherapeutics, another listed company it helped set up, added to the loss.
It ended the year with £1.0m in cash and no borrowings, after raising £750k from shareholders. No dividend was paid. Management reported record orders of more than £800k in the first weeks of 2026 and expects cost cuts to move the business towards profit. The auditor raised no doubt about the company's ability to keep going. However, trading in SkinBioTherapeutics shares was suspended in March 2026 after an investigation into that company's former boss.
SlimBiome weight-management product, positioned as a safe, lower-cost alternative/complement to GLP-1 agonists
SlimBiome is our flagship weight loss product, clinically proven through four human studies...We have changed our focus to promoting SlimBiome as both a safe and lower cost natural alternative to GLP-1s, and increasingly as an aid to preventing weight gain when consumers stop injecting the drugs
page 7Gross margin improvement from product mix and cost discipline
The Group increased its gross profit from 38% in 2024 to 53% in 2025...gross profit which has increased by 85% to £614k (2024: £331k)
page 8We made a very strong start to the new financial year, with record orders of more than £800k from four major partners recorded in the first four weeks of 2026...With tighter cost control delivering improved margins across the Group, and an important breakthrough achieved as we move towards the commercialisation of SweetBiotix, we believe that we are on course to achieve our objective of moving all parts of the business towards profitability.
page 4No dividends were distributed for the year to 31 December 2025 (2024: nil). The CEO report notes the Group's equity stakes in SBTX and PBX 'provide opportunities to realise value through the sale of shares or the potential of an ad hoc dividend return to shareholders.'
page 1411 years on one page · FY2015–FY2025
| Line | FY2015locked | FY2016locked | FY2017locked | FY2018locked | FY2019locked | FY2020locked | FY2021locked | FY2022locked | FY202312/23 | FY202412/24 | FY202512/25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Operating profit | |||||||||||
| Profit for the year | |||||||||||
| Basic EPS | |||||||||||
| Dividend per share | — | ||||||||||
| Free cash flow | |||||||||||
| Net debt (negative = net cash) | |||||||||||
| Shares in issue | |||||||||||
| Operating margin | |||||||||||
| Return on capital employed |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
5 figures restated in a later report
Every figure is read again from the following year’s report: 279 confirmed, 6 differ, 5 restated.
No figure has been restated: every figure a later report printed again, it printed the same.
5 more figures were restated in FY2015 to FY2022, which a free account opens.